TGF-β inhibitors offer potential antifibrotic and anticancer therapeutic benefits for the treatment of cardiac fibrosis and cancer based on available clinical data.
Targeting TGF-β signaling pathways represents a promising therapeutic strategy for the treatment of both cardiac fibrosis and cancer.
Absolute Event Rate: 0% vs 0%
evidence regarding antifibrotic and anticancer actions of TGF-β inhibitors. In addition, we also present available clinical data on therapy based on inhibiting TGF-β signaling for the treatment of cancers and cardiac fibrosis.
Parichatikanond et al. (Tue,) reported a other. TGF-β inhibitors offer potential antifibrotic and anticancer therapeutic benefits for the treatment of cardiac fibrosis and cancer based on available clinical data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: